A new initiative to rapidly place individuals with acute myeloid leukemia or myelodysplastic syndrome in clinical trials based on their genomic profiles has opened in the United States and Canada.
The myeloMATCH program will enroll patients into different studies as their cancer progresses, aiming to use precision medicine approaches to target residual disease.
“We have so many large phase 3 trials that have turned out negative, and this is a drain on resources — both the number of patients and the time and opportunity loss,” Richard F. Little, MD, NCI coordinator for
